Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS: MAJIC-PV is a randomized phase II trial of ruxolitinib versus...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Claire N., Nangalia, Jyoti, Boucher, Rebecca, Jackson, Aimee, Yap, Christina, O'Sullivan, Jennifer, Fox, Sonia, Ailts, Isaak, Dueck, Amylou C., Geyer, Holly L., Mesa, Ruben A., Dunn, William G., Nadezhdin, Eugene, Curto-Garcia, Natalia, Green, Anna, Wilkins, Bridget, Coppell, Jason, Laurie, John, Garg, Mamta, Ewing, Joanne, Knapper, Steven, Crowe, Josephine, Chen, Frederick, Koutsavlis, Ioannis, Godfrey, Anna, Arami, Siamak, Drummond, Mark, Byrne, Jennifer, Clark, Fiona, Mead-Harvey, Carolyn, Baxter, Elizabeth Joanna, McMullin, Mary Frances, Mead, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306428/
https://www.ncbi.nlm.nih.gov/pubmed/37126762
http://dx.doi.org/10.1200/JCO.22.01935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306428/
https://www.ncbi.nlm.nih.gov/pubmed/37126762
http://dx.doi.org/10.1200/JCO.22.01935

Ejemplares similares